(Research Journal published by college)
Pharmacum Consequat is international, biannual, peer-reviewed journal, published under the auspices of Shree Warana Vibhag Shikshan Mandal’s, Tatyasaheb Kore College of Pharmacy, Warnanagar. It publishes review articles and original research work, contributing significantly to conduct research into promising drug candidate compounds in order to deliver pharmaceutical products to patients as a “good medicine.”
It is the mission of pharmaceutical research to take a path from understanding a disease to bringing a safe and effective new treatment to patients. Scientists work to section together the basic causes of disease at the molecular level to understand emerging targets; which potential new drugs might be able to affect.
Drug Discovery and Pharmaceutical Product Development (DDPPD) is designed to ensure that only safe and effective products are brought to market, providing a broad array of drug discovery and development services, ranging from drug discovery through clinical studies and post-approval support.
The sequence of research activities begins a process that results in development of new medicines; includes Target Identification, Target Prioritization/ Validation, Lead Identification and Lead Optimization.
In the preclinical stage of drug development, an investigational drug must be tested extensively in the laboratory to ensure that it will be safe to administer to humans through Preclinical Technology, Chemistry Manufacturing and Controls (CMC) and Pharmacology/Toxicology.
Pharmaceutical development; first stage in the product development process, is wherein the molecules discovered in the drug discovery phase are turned into medicines.
The goal of pharmaceutical development is developing novel and improved, high quality pharmaceutical products in a cost-effective way and continuing to support those products throughout their life cycle.
This will involve Pharmaceutical formulation, Process development, Pharmaceutical analysis and Pharmaceutical maintenance, which includes improvements or changes in manufacturing processes, formulation, or analytical methods.
Post-submission of information, a new drug is tested and permission is desired vide application so as to begin administration to healthy volunteers and patients. It proceeds through Investigational New Drug (IND)/Clinical Trial Exception (CTX)/Clinical Trial Authorization (CTA) Applications, Phase I Clinical Studies, Phase II Clinical Studies, Phase III Clinical Studies and New Drug Application (NDA in the U.S.)/ Marketing Authorization Application (MAA in the U.K.)
Post-approval of an new drug by a regulatory agency, pharmaceutical companies conduct additional studies, including Phase IIIb and Phase IV studies. Late-stage drug development studies of approved, marketed drugs may continue for several months to several years.